Exploring High-Risk Hypertension Characteristics in Cryptogenic Stroke: Insights from the ARCADIA Randomized Study

By
Mohamed Ridha
Raed Hailat
Robert Stanton
Alexander E. Merkler
Mitchell S. V. Elkind
W. T. Longstreth
David L. Tirschwell
Richard A. Kronmal
Yousef Hannawi
Hooman Kamel
James Burke
Daniel Woo
June 1, 2026

Jama Neurology

Objective:

To examine whether hypertension risk stratification modifies the effect of anticoagulation compared to antiplatelet therapy in patients with cryptogenic stroke.

Key Findings:

25% to 30% of ischemic strokes are cryptogenic, likely involving multiple mechanisms.
Anticoagulation has not shown superiority over antiplatelet therapy in trials for embolic stroke of undetermined source.
Hypertension-related cerebrovascular disease may obscure the benefits of anticoagulation.

Interpretation:

Remove this section as it contains unsupported conclusions.

Limitations:

The analysis was not prespecified in the trial protocol.
Results may be influenced by the inclusion of patients with severe hypertension.

Conclusion:

Revise to eliminate speculative language and focus on findings directly supported by the study.

Exploring High-Risk Hypertension Characteristics in Cryptogenic Stroke: Insights from the ARCADIA Randomized Study

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized

Related Content

Tenecteplase vs Alteplase and Time to Treatment for Acute Ischemic Stroke

Anticoagulation in Device-Detected Atrial Fibrillation—Uncertainty and Heterogeneity in Value

‘It works in practice, but does it work in theory?’ An important addition to the body of real-world evidence supporting carotid endarterectomy